Payment overview · 2025
General Payments
$194.32
10 reported records · 5 companies
Healthcare provider profile · identity verified
Doyle Claude Phillips, MD
Allopathic & Osteopathic Physicians|Family Medicine · OCALA, FL · NPI 1669478467
Verified facts
What the public records show
CMS Open Payments records show Doyle Claude Phillips, MD received $194.32 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Nurtec Odt.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.71 | 52.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.89 | 16.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.40 | 12.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.27 | 9.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.05 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $194.32 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $102.71 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $52.85 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.86 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 537 | 147 |
| Gabapentin | Gabapentin | 436 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 127 |
| Losartan Potassium | Losartan Potassium | 394 | 118 |
| Famotidine | Famotidine | 378 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 377 | 123 |
| Lisinopril | Lisinopril | 307 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 287 | 81 |
| Alprazolam | Alprazolam | 244 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 228 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 58 |
| Trazodone Hcl | Trazodone Hcl | 218 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 214 | 65 |
| Metformin Hcl | Metformin Hcl | 212 | 65 |
| Furosemide | Furosemide | 211 | 68 |
| Omeprazole | Omeprazole | 202 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 182 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 51 |
| Carvedilol | Carvedilol | 138 | 40 |
| Potassium Chloride | Potassium Chloride | 129 | 45 |
| Meloxicam | Meloxicam | 128 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 39 |
| Baclofen | Baclofen | 116 | 35 |
| Methocarbamol | Methocarbamol | 113 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | 15 |
| Simvastatin | Simvastatin | 113 | 36 |
| Azithromycin | Azithromycin | 106 | 84 |
| Montelukast Sodium | Montelukast Sodium | 101 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 98 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 28 |
| Tramadol Hcl | Tramadol Hcl | 97 | 25 |
| Clonazepam | Clonazepam | 96 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 95 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 95 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 24 |
| Jardiance | Empagliflozin | 92 | 21 |
| Lorazepam | Lorazepam | 91 | 26 |
| Farxiga | Dapagliflozin Propanediol | 87 | 20 |
| Glimepiride | Glimepiride | 82 | 24 |
| Buspirone Hcl | Buspirone Hcl | 81 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 78 | 11 |
| Eliquis | Apixaban | 76 | 19 |
| Atenolol | Atenolol | 75 | 20 |
| Allopurinol | Allopurinol | 74 | 24 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 74 | 61 |
| Methylprednisolone | Methylprednisolone | 74 | 63 |
| Prednisone | Prednisone | 70 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 14 |
| Clonidine Hcl | Clonidine Hcl | 67 | 17 |
| Synthroid | Levothyroxine Sodium | 62 | 14 |
| Donepezil Hcl | Donepezil Hcl | 61 | 24 |
| Alendronate Sodium | Alendronate Sodium | 59 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 18 |
| Naproxen | Naproxen | 57 | 14 |
| Metformin Hcl Er | Metformin Hcl | 56 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 15 |
| Spironolactone | Spironolactone | 55 | 12 |
| Finasteride | Finasteride | 54 | 17 |
| Mirtazapine | Mirtazapine | 53 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 37 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 35 |
| Amoxicillin | Amoxicillin | 47 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 33 |
| Cephalexin | Cephalexin | 45 | 34 |
| Fenofibrate | Fenofibrate | 45 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 24 |
| Pregabalin | Pregabalin | 44 | 14 |
| Valacyclovir | Valacyclovir Hcl | 44 | 14 |
| Rybelsus | Semaglutide | 43 | 15 |
| Ibuprofen | Ibuprofen | 42 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 12 |
| Ozempic | Semaglutide | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Diazepam | Diazepam | 37 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 13 |
| Primidone | Primidone | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 12 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Estradiol | Estradiol | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 16 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Topiramate | Topiramate | 26 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Colchicine | Colchicine | 24 | 13 |
| Glipizide | Glipizide | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Qelbree | Viloxazine Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $194.32 · 10 records | PFIZER INC. | Cologuard Collection Kit, ELIQUIS, JARDIANCE, NURTEC ODT, VOQUEZNA, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error